From: Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients
Dose, mg/day
Dose-titration phase (n= 39)
Parallel-group phase
Lanthanum carbonate (n= 10)
Placebo (n= 11)
375
5 (12.8)
1 (10.0)
0 (0.0)
750
11 (28.2)
3 (30.0)
4 (36.4)
1500
14 (35.9)
2250
9 (23.1)
3 (27.3)